氨甲酸,(7-羟基-1-萘基)-,苯基酯 | 151067-74-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 中文名称: 氨甲酸,(7-羟基-1-萘基)-,苯基酯
• 英文名称: phenyl 7-hydroxy-1-naphthylcarbamate
• 英文别名: (7-hydroxy-naphthalen-1-yl)-carbamic acid phenyl ester；2-Hydroxy-8-phenyloxycarbonylaminonaphthalene；phenyl N-(7-hydroxynaphthalen-1-yl)carbamate
• CAS: 151067-74-2
• 化学式: C₁₇H₁₃NO₃
• 分子量: 279.295
• InChiKey: SFTAYEXZRWGVSP-UHFFFAOYSA-N

物化性质

• 沸点：
  467.5±27.0 °C(Predicted)
• 密度：
  1.349±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  58.6
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-乙基苄胺 、 氨甲酸,(7-羟基-1-萘基)-,苯基酯 以 二甲基亚砜 为溶剂， 生成 1-苄基-1-乙基-3-(7-羟基萘-1-基)脲
  参考文献：
  名称：

  7-Hydroxynaphthalen-1-yl-urea and -amide antagonists of human vanilloid receptor 1

  摘要：

  A series of structurally simple 7-hydroxynaphthalenyl ureas and amides were discovered to be potent ligands of human vanilloid receptor I (VR1). 1-(7-Hydroxynaphthaten-1-yl)-3-(4-trifluoromethylbenzyl)urea 5f exhibited nanomolar binding affinity (K-i = 1.0 nM) and upon capsaicin challenge, behaved as a potent functional antagonist (IC50 = 4 nM). The synthesis and structure-activity relationships (SARs) for the series are described. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2003.09.090
• 作为产物：
  描述：

  1-氨基-7-萘酚 、 氯甲酸苯酯 在 吡啶 作用下， 生成 氨甲酸,(7-羟基-1-萘基)-,苯基酯
  参考文献：
  名称：

  Discovery of dual-acting opioid ligand and TRPV1 antagonists as novel therapeutic agents for pain

  摘要：

  In order to discover a novel type of analgesic, we investigated dual activity ligands with TRPV1 antagonism and mu-opioid receptor affinity with the goal of eliciting synergistic analgesia while avoiding the side effects associated with single targeting. Based on a combination approach, a series of 4-benzyl-4-(dimethylamino)piperidinyl analogues were designed, synthesized and evaluated for their receptor activities. Among them, compound 49 exhibited the most promising dual-acting activity toward TRPV1 and the mu-opioid receptor in vitro. In vivo, 49 displayed potent, dose-dependent antinociceptive activity in both the 1st and 2nd phases in the formalin assay. Consistent with its postulated mechanism, we confirmed that in vivo, as in vitro, compound 49 both antagonized TRPV1 and functioned as a mu-opioid agonist. This result indicates that dual-acting TRPV1 antagonist/mu-opioid ligands can be made and represent a new and promising class of analgesic. (C) 2019 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2019.111634

文献信息

• Naphthol, quinoline and isoquinoline-derived urea modulators of vanilloid VR1 receptor
  申请人：——

  公开号：US20040157865A1

  公开（公告）日：2004-08-12

  This invention is directed to vanilloid receptor VR1 ligands. More particularly, this invention relates to naphthol, quinoline and isoquinoline-derived ureas that are potent antagonists or agonists of VR1 which are useful for the treatment and prevention of inflammatory and other pain conditions in mammals.

  本发明涉及辣椒素受体VR1配体。更具体地说，本发明涉及萘酚，喹啉和异喹啉衍生的脲类化合物，它们是VR1的有效拮抗剂或激动剂，对哺乳动物的炎症和其他疼痛症状的治疗和预防有用。
• Ether derivative
  申请人：Okuzumi Tatsuya

  公开号：US20060270693A1

  公开（公告）日：2006-11-30

  The present invention relates to an ether derivative represented by the formula (I), a pharmaceutically acceptable salt thereof, a hydrate thereof or a solvate thereof wherein each symbol is as defined in the description, and an ether derivative represented by the formula (III), a pharmaceutically acceptable salt thereof, a hydrate thereof or a solvate thereof wherein each symbol is as defined in the description; a pharmaceutical composition containing the ether derivative; and a package containing the pharmaceutical composition and a description of use thereof. A pharmaceutical composition of the present invention, which contains this compound of the present invention has a superior anti-inflammatory and analgesic activity and is useful as various pharmaceutical agents such as an anti-inflammatory agent, an analgesic, a therapeutic agent for inflammatory bowel disease, a therapeutic agent for pollakiuria and/or incontinentia, a therapeutic agent for asthma and the like.

  本发明涉及一种以式(I)表示的醚衍生物，其药学上可接受的盐、水合物或溶剂化物，其中每个符号如描述中所定义的，并且一种以式(III)表示的醚衍生物，其药学上可接受的盐、水合物或溶剂化物，其中每个符号如描述中所定义的；一种含有该醚衍生物的制药组合物；以及一个包含该制药组合物及其使用说明的包装。本发明的制药组合物，包含该化合物具有优异的抗炎和镇痛活性，并且可用作各种药物剂型，如抗炎剂、镇痛剂、治疗炎症性肠病的治疗剂、治疗排尿过频和/或失禁的治疗剂、治疗哮喘等。
• Heat-sensitive recording materials and phenol compounds
  申请人：MITSUI TOATSU CHEMICALS, Inc.

  公开号：EP0524419A1

  公开（公告）日：1993-01-27

  Heat-sensitive recording materials contain an electron-donating chromogenic compound and an electron-attracting compound. The recording materials also contain at least one compound represented by the following formula: wherein R₁ and R₃ mean a hydrogen atom or an alkyl, aralkyl or aryl group, R₂ and R₄ denote an alkyl, alkenyl, aralkyl or aryl group, X₁, X₂, Y₁ and Y₂ stand for an oxygen or a sulfur atom, and -Z₁- and -Z₂- are a specific aromatic group. Also provided are phenol compounds represented by the following formula: wherein R₁, R₂, X₁ and Y₁ have the same meanings as defined above; R₅ and R₆ are a hydrogen or halogen atom or an alkyl, alkoxy, aralkyl, aryl or hydroxyl group; p and q stand for an integer of 1-4; R₅ and R₆ may be either the same or different when p and q represent an integer of 2 or greater; and -Z₃- means a specific divalent group.

  热敏记录材料含有一种电子供体变色化合物和一种电子吸引化合物。记录材料还含有至少一种由下式表示的化合物： 其中 R₁ 和 R₃ 表示氢原子或烷基、芳基或芳基，R₂ 和 R₄ 表示烷基、烯基、芳基或芳基，X₁、X₂、Y₁ 和 Y₂ 表示氧原子或硫原子，-Z₁- 和 -Z₂- 是特定的芳香基团。还提供由下式表示的苯酚化合物： 其中 R₁、R₂、X₁ 和 Y₁ 的含义与上述定义相同；R₅ 和 R₆ 是氢原子或卤素原子或烷基、烷氧基、芳基、芳基或羟基；p 和 q 代表 1-4 的整数；当 p 和 q 代表 2 或更大的整数时，R₅ 和 R₆ 可以相同或不同；以及 -Z₃- 指特定的二价基团。
• ETHER DERIVATIVE
  申请人：Ajinomoto Co., Inc.

  公开号：EP1679296A1

  公开（公告）日：2006-07-12

  The present invention relates to an ether derivative represented by the formula (I), a pharmaceutically acceptable salt thereof, a hydrate thereof or a solvate thereof wherein each symbol is as defined in the description, and an ether derivative represented by the formula (III), a pharmaceutically acceptable salt thereof, a hydrate thereof or a solvate thereof wherein each symbol is as defined in the description; a pharmaceutical composition containing the ether derivative; and a package containing the pharmaceutical composition and a description of use thereof. A pharmaceutical composition of the present invention, which contains this compound of the present invention has a superior anti-inflammatory and analgesic activity and is useful as various pharmaceutical agents such as an anti-inflammatory agent, an analgesic, a therapeutic agent for inflammatory bowel disease, a therapeutic agent for pollakiuria and/or incontinentia, a therapeutic agent for asthma and the like.

  本发明涉及一种由式（I）表示的醚衍生物、其药学上可接受的盐、其水合物或其溶液 其中各符号如描述中所定义，以及由式（III）表示的醚衍生物、其药学上可接受的盐、其水合物或其溶物 其中各符号在说明中定义；含有醚衍生物的药物组合物；以及含有药物组合物及其使用说明的包装。含有本发明化合物的本发明药物组合物具有优异的抗炎和镇痛活性，可用作各种药物制剂，如抗炎剂、镇痛剂、炎症性肠病治疗剂、花粉尿症和/或失禁治疗剂、哮喘治疗剂等。
• EP1679296
  申请人：——

  公开号：——

  公开（公告）日：——